Main Menu

Novel CD8+ T cell receptors (TCRs) isolated from elite HIV controllers show unprecedented affinity for conserved HIV epitopes, offering new avenues for direct immunotherapies and T cell engineering. These TCRs exhibit potential for cytotoxicity mediation against HIV-infected cells, with prospects for use in toxin-coupled treatments or as part of engineered T cell therapies. Collaborations, such as with Altor Biosciences, are enhancing these TCRs with proprietary molecules like IL-15, to bolster therapeutic efficacy.

The technology revolves around an innovative monoclonal antibody-based conditioning regimen for enhancing the engraftment of hematopoietic stem cells during bone marrow transplants. It features a novel antibody-drug conjugate that targets CD117, a marker on stem cells, to enable effective transplantation without the harmful side effects of traditional conditioning methods.

The technology pertains to a novel polymer nanoparticle platform designed for the creation of individualized cancer vaccines. It utilizes a two-component system that combines patient-specific peptide neoantigens with immunostimulants within self-assembling nanoparticles. This approach ensures the targeted delivery of neoantigens to the immune system, enhancing the immune response against cancer cells while avoiding the systemic activation often seen with conventional adjuvants.

The technology encompasses a novel set of fully human monoclonal antibodies targeting the spike (S) protein of coronaviruses, notably the SARS-CoV-2 virus responsible for COVID-19. These antibodies, derived from convalescent patients, offer potential for use in the diagnosis, monitoring, and treatment of coronavirus infections. This discovery includes a comprehensive library of antibody or antibody fragment candidates with high specificity for the coronavirus spike protein.

This technology presents a novel strain of transgenic mice where the proto-oncogene c-Cbl (Casitas B-lineage lymphoma) has been engineered with loxP (locus of X-over P1) sites, commonly referred to as "floxed." This design enables the conditional knockout of the c-Cbl gene when the mice are crossed with strains that express the Cre recombinase enzyme. Cre recombinase is an enzyme that can specifically target loxP sites, excising the floxed gene only in the presence of Cre, thus allowing tissue-specific or temporal deletion of the target gene.

The technology pertains to the development of furin-deficient Chinese Hamster Ovary (CHO) cells, specifically the CHO FD11 cell line, which plays a pivotal role in proteolytic maturation of various proteins critical for physiological processes and pathogen virulence. By inhibiting furin, a protease involved in the activation of many important proteins and pathogens, these modified cells provide a unique platform for research into viral infections and potential therapeutic interventions.

The technology pertains to a novel multivalent peptide tolerogen designed for the therapeutic treatment of Multiple Sclerosis (MS), a condition where the immune system erroneously attacks the central nervous system. This advanced therapeutic strategy involves a fusion-peptide composed of myelin oligodendrocyte glycoprotein (MOG), myelin-basic protein (MBP), and myelin proteolipid protein (PLP), along with myelin-associated glycoprotein (MAG).

The PSY2 Bovidae aurbeta/gamma shuttle vector represents a pioneering technology in the field of genetic engineering. This innovative vector system has been designed for use in Bovidae species, potentially offering a novel approach to gene delivery and manipulation. It leverages a dual-functionality mechanism that could enable both autonomous replication and the precise insertion of genetic material.

The discovery of antimicrobial-resistant Staphylococcus aureus strains NR-46192 and NR-46201 represents a significant advancement in the study and treatment of antibiotic resistance. Isolated from patient samples and resistant to multiple antibiotics, these strains offer valuable insights into the mechanisms of resistance and provide a critical resource for antimicrobial research and testing.

The discovery of RPS3 and phospho-RPS3 antibodies represents a significant advancement in understanding mammalian gene regulation and its implications for disease. These antibodies serve as critical tools for detecting and studying the NF-kB transcription factor, particularly its specifier subunit RPS3 and its phosphorylated form.